Trellis to Provide Cell Line Development Services to PDL BioPharma
Complete the form below to unlock access to ALL audio articles.
Trellis Bioscience has announced that it has signed an agreement with PDL BioPharma to provide cell line development services using Trellis' Antibody CellSpot™ technology.
Antibody CellSpot™ allows for in-depth analysis and characterization of millions of individual antibody-producing cells for multiple properties, such as the affinity, specificity and secretion rate, and is coupled to a proprietary method for harvesting single cells.
The platform can screen diverse libraries of cells at an unprecedented level of depth and detail and operates with a simplicity and speed that can shave months from the normal development and manufacturing cycle for an antibody candidate.
"Our work with PDL BioPharma will allow us to demonstrate the power of CellSpot™," said Nolan Sigal, M.D., Ph.D., President of Trellis Bioscience.
"PDL BioPharma is a world leader in the discovery and development of antibodies, and we are excited to be working with them."
